MétaCan
Menu
Back to cohort

Ventricular arrhythmias and nonsedating antihistamines

2000· letter· en· W1577439301 on OpenAlexaff
Samy Suissa

Bibliographic record

VenueBritish Journal of Clinical Pharmacology · 2000
Typeletter
Languageen
FieldMedicine
TopicAsthma and respiratory diseases
Canadian institutionsRoyal Victoria HospitalMcGill University
Fundersnot available
KeywordsTerfenadineAntihistamineAstemizoleMedicineRelative riskAdverse effectCohortAdverse Event Reporting SystemIncidence (geometry)FexofenadineDrugInternal medicineAnesthesiaPharmacologyConfidence interval

Abstract

fetched live from OpenAlex

De Abajo & Rodriguez carried out a cohort study with a nested-case control analysis to assess and quantify the risk of ventricular dysrhythmia associated with the use of five nonsedating antihistamine drugs [1]. Two observations from this study merit further discussion. First, although the study reports a low incidence rate of such events (1.9/10 000 patient/years; 95%CI: 1.0–3.6) after nonsedating antihistamine use, this rate is surprisingly four times higher than the rate during nonuse. Second, the relative risk (RR) observed for terfenadine (RR = 2.0) is remarkably low when compared with astemizole (RR = 17.8) or cetirizine (RR = 7.1). This is somewhat unexpected since previous large-scale epidemiological studies found that terfenadine users had risks similar to that of users of sedating antihistamines and ibuprofen [2, 3], while an analysis of WHO spontaneous adverse drug reports suggested that terfenadine may carry similar or larger risks of serious ventricular dysrhythmia than other antihistamines [4]. These unusual findings may be related to unidentified methodological limitations of the study design that could have biased the estimates. First, depletion of susceptibles may have occurred because the reference group of ‘non use’ was formed with the time period following the use of nonsedating antihistamine drugs. Thus, because only the first ventricular dysrhythmia event was considered, subjects for whom this cardiac event occurred during the initial drug exposure were ineligible for inclusion in the reference ‘nonuse’ group, which was thereby depleted of these possibly high-risk subjects. Consequently, if some subjects were more susceptible to develop ventricular dysrhythmias, the study design forced them into the exposed group. This will necessarily underestimate the incidence rate in the nonuse reference group, thereby artificially increasing the overall RR and the RR for individual nonsedating antihistamines. Second, since terfenadine prescriptions decreased by 52% during the follow-up period (Jan 92-Sept 96), major changes in prescribing habits were taking place. This figure suggests that a large number of subjects initially started on terfenadine were switched to other agents sometime during the follow-up period. If the reason for switching was related to the risk of ventricular dysrhythmias, with switchers being more at risk, disproportionately higher relative risks will be observed with other agents. Finally, it was noted that total prescriptions of nonsedating antihistamines decreased roughly from 10 000 to 7000 per month. Thus, we can deduce that the use of nonprescription antihistamine drugs during the follow-up period, which was not considered in the study, may have been increasing to compensate the decrease in prescriptions. Consequently, the rate of ventricular dysrhythmia in the reference ‘nonuse’ group will likely increase over the span of the study. Whether this phenomenon affects the rate ratios in any way was not assessed. Based on these limitations in study design and data analysis, the relative risks reported (1) may be biased. Any future epidemiological study conducted to confirm these findings should: (1) include a concurrent reference group composed of genuine nonusers of nonsedating antihistamines, (2) assess whether depletion of susceptibles was present, (3) consider changes in prescription patterns over time in the data analysis and (4) assess the effect of calendar time when estimating the relative risks to account, at least in part, for time trends in the unavailable nonprescription exposures. Received 30 September 1999, accepted 23 December 1999.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.009
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Commentary · Consensus signal: none
Teacher disagreement score0.004
Threshold uncertainty score0.016

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.009
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0010.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.037
GPT teacher head0.382
Teacher spread0.345 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2000
Admission routes1
Has abstractyes

Explore more

Same venueBritish Journal of Clinical PharmacologySame topicAsthma and respiratory diseasesFrench-language works237,207